GSK strengthens vaccines business with acquisition of Okairos

GlaxoSmithKline (GSK) today announced that it has acquired Okairos AG (Okairos), a specialist developer of vaccine platform technologies for €250 million (approximately £215 million/$325 million) in cash.
Source: GSK news - Category: Pharmaceuticals Source Type: news